FHTXMEDIUM SIGNALFINANCIAL10-K

FHTX showed strong revenue growth of 37% and meaningful improvement in operating losses, while significantly increasing cash position despite reduced total assets.

The company demonstrates positive operational momentum with substantial revenue growth and 16% improvement in operating losses, suggesting better execution of their precision oncology strategy. However, the 95% decline in interest expense alongside major balance sheet contraction indicates potential restructuring or asset sales that warrant closer examination of the underlying business changes.

Comparing 2026-03-11 vs 2025-03-06View on EDGAR →
FINANCIAL ANALYSIS

FHTX delivered strong top-line growth with revenue increasing 37% to $30.9M and meaningfully improved profitability metrics, including 16% reductions in both operating losses and net losses. The company strengthened its cash position by 46% to $80.9M, providing better runway for operations, though this came alongside a 30% reduction in total assets suggesting potential asset optimization or restructuring. The 95% drop in capital expenditures and overall balance sheet contraction indicate the company may be in a transitional phase, focusing resources on core operations while maintaining adequate liquidity.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
+94.7%
$979K$1.9M

Interest expense surged 94.7% — significant debt increase or rising rates materially impacting earnings.

Capital Expenditure
Cash Flow
-94.5%
$906K$50K

Capex reduced 94.5% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Cash & Equivalents
Balance Sheet
+45.8%
$55.5M$80.9M

Cash position surged 45.8% — strong cash generation or capital raise providing significant financial cushion.

Revenue
P&L
+36.8%
$22.6M$30.9M

Strong top-line growth of 36.8% — accelerating demand or successful expansion into new markets.

Current Assets
Balance Sheet
-34.6%
$249.6M$163.2M

Current assets declined 34.6% — monitor working capital adequacy and short-term liquidity.

Total Assets
Balance Sheet
-30.2%
$284.0M$198.1M

Total assets contracted 30.2% — asset sales, write-downs, or balance sheet optimization underway.

Operating Income
P&L
+15.9%
-$102.7M-$86.4M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Net Income
P&L
+14.2%
-$86.6M-$74.3M

Net income grew 14.2% — bottom-line growth signals improving overall business health.

Operating Cash Flow
Cash Flow
+14.2%
-$100.4M-$86.1M

Operating cash flow grew 14.2% — strong conversion of earnings to cash, healthy business fundamentals.

Current Liabilities
Balance Sheet
-10.8%
$67.0M$59.7M

Current liabilities reduced — improved short-term financial position and working capital health.

LANGUAGE CHANGES
NEW — 2026-03-11
PRIOR — 2025-03-06
ADDED
As of February 27, 2026 there were 58,700,246 shares of the registrant s common stock, par value $0.0001 per share, outstanding.
Our Gene Traffic Control platform encompasses the following: Target Identification and Validation We use genomic screens, and a suite of epigenome sequencing and computational tools, including aspects of artificial intelligence and machine learning, to characterize, identify, and validate targets within the chromatin regulatory system.
We have assembled an exceptional team of 106 employees as of December 31, 2025.
To achieve our mission, we are executing a strategy with the following key elements: Advance our lead precision oncology product candidate, FHD-909, through clinical development in patients with NSCLC and with select solid tumors with partner Lilly.
For example, using our proprietary platform, we have disclosed four distinct targets: SMARCA2, CBP, EP300 and ARID1B , that have genetically determined dependencies within the chromatin regulatory system.
+7 more — sign up free →
REMOVED
As of February 28, 2025 there were 55,612,239 shares of the registrant s common stock, par value $0.0001 per share, outstanding.
We combine our genomic and epi-genomic tools, our proprietary high throughput screening technology and our expertise in medicinal chemistry to develop enzymatic inhibitors, protein degraders and transcription factor disruptors that target the chromatin regulatory system.
In addition, we are developing binders to a new ligase, UBR5.
UBR5 operates in the nucleus to degrade various transcription factors, and our goal is to develop a new option to degrade transcription factors and other important targets.
We have assembled an exceptional team of 112 employees as of December 31, 2024.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →